RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo CD3 protiens have become a hot target for bispecific antibodies. T cell bispecific antibodies (TCBs) are molecules that are engineered to include binding sites to the T cell receptor (TCR) and to tumor-associated or tumor-specific antigens within a single entity. One of the most widely studied TCBs in cancer immunotherapy is CD3, a molecule that has the function of stabilizing TCR structure and transmitting activation signals.
Antibodies against CD3 molecules can stimulate or block T cell activation signal transduction. In addition, these antibodies can eliminate effector T cells or induce a regulatory phenotype in T cells thus, providing a new method for the treatment of organ transplant rejection and autoimmune diseases. These CD3 molecules bind to TCR non-covalently to form a TCR/CD3 receptor complex on the surface of the T cell.
The ability of a monoclonal antibody (mAb) to bind a specific antigen, such as a protein or epitope, on the surface of a cell has led to a variety of therapeutic applications. In particular, derivatives like antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) in cancer treatment have been developed. Whereas ADCs are designed to deliver a toxic payload to malignant tissue, bsAbs bind different epitopes such as antigens on separate target cells. Currently, T cell or NK cell redirectors and tumor-targeted immunomodulators form the main class of bsAbs, which makes ONCY's pelareorep a very attractive agent for bioconjugation with the CD3 protein bispecific antibody, particularly since ONCY and SOLTI has demonstrated that pelareorep enhances T-cell receptors (TCR) and the expansion of new and existing tumor infiltrating lymphocytes (TiLs) in the blood.
https://www.newswire.ca/news-releases/oncolytics-biotech-r-and-solti-present-positive-translational-data-at-sabcs-832342590.html